Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant EC Aspirin, Rintatolimod, and Interferon-alpha 2b in Localized Prostate Cancer
NCT03899987Phase 2Active, not recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Nov 2019
- Primary completion
- Apr 2027
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of rintatolimod in prostate cancer (PCa), sponsored by Roswell Park Comprehensive Cancer Center. Started Nov 2019; status: active, not recruiting.
02
Drugs
rintatolimod
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03899987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899987.